Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

Condition:   Relapsing Remitting Multiple Sclerosis Interventions:   Drug: Personalized extended interval dosing of natalizumab;   Drug: Standard interval dosing Sponsors:   VU University Medical Center;   Stichting MS Research;   Innovatiefonds Zorgverzekeraard Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials